A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.

Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.

The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.